Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

Na, Soo‐Young; Kim, You Sun

doi:10.3904/kjim.2022.152

Cited by 6 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Vedolizumab is currently used as an effective treatment modality for IBD. 44,45 Considering the mechanism of action of the drug and the over-expression of MAdCAM-1 in the hepatic endothelial cells of PSC, vedolizumab was expected to be a potential candidate for the treatment of PSC-IBD. In a large retrospective study by the International PSC Study Group, 102 patients with PSC-IBD who received at least 3 doses of vedolizumab were evaluated.…”

Section: Ibd Treatmentmentioning

confidence: 99%

“…Vedolizumab inhibits the α4β7 integrin–mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) interaction, which blocks lymphocyte trafficking to inflammation site of the gastrointestinal tract [ 43 ]. Vedolizumab is currently used as an effective treatment modality for IBD [ 44 , 45 ]. Considering the mechanism of action of the drug and the over-expression of MAdCAM-1 in the hepatic endothelial cells of PSC, vedolizumab was expected to be a potential candidate for the treatment of PSC-IBD.…”

Section: Current Treatment Modalities Of Psc-ibdmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease

Kim¹,

Hurley²,

Park³

et al. 2023

Intest Res

Self Cite

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with this disease have an increased risk of malignancy development, such as colorectal cancer and cholangiocarcinoma. The pathogenesis of PSC-IBD involves genetic and environmental factors such as gut dysbiosis and bile acids alteration. However, despite the advancement of disease characteristics, no effective medical therapy has proven to have a significant impact on the prognosis of PSC. The treatment options for patients with PSC-IBD do not differ from those for patients with PSC alone. Potential candidate drugs have been developed based on the pathogenesis of PSC-IBD, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis. In this review, we summarize the current medical treatments for PSC-IBD and the status of new emerging therapeutic agents.

show abstract

Section: Ibd Treatmentmentioning

confidence: 99%

Section: Current Treatment Modalities Of Psc-ibdmentioning

confidence: 99%

Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease

Kim¹,

Hurley²,

Park³

et al. 2023

Intest Res

Self Cite

View full text Add to dashboard Cite

show abstract

Dopamine β-hydroxylase shapes intestinal inflammation through modulating T cell activation

Sun,

Li,

et al. 2024

Cellular Immunology

View full text Add to dashboard Cite

Meta-analysis of etrolizumab versus placebo in ulcerative colitis: safety and efficacy outcomes

Zhang,

Jia,

Piao

2024

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: The existing body of scientific literature offers inconclusive findings on the safety and therapeutic effectiveness of etrolizumab (ETR) for the treatment of ulcerative colitis (UC). Objectives: The goal of this meta-analysis is to furnish a comprehensive synthesis of evidence that evaluates the safety and therapeutic effects of ETR in the management of UC. Design: Meta-analysis. Data sources and methods: PubMed, Embase, and Web of science were searched to collect relevant English studies, and the reference lists of eligible studies were manually searched to avoid missing any eligible studies. Outcome measures encompassed clinical response, incidence of adverse events, histological remission, endoscopic remission, endoscopic improvement, and antidrug antibodies. Relevant data were extracted by two independent investigators. Results: The meta-analysis incorporated five eligible studies, involving a total of 1528 patients, with 1015 treated with ETR and 513 with placebo. The pooled analysis indicates that ETR is both effective and safe. The adverse event rates, endoscopic and histological response, as well as overall remission were comparable between the two groups. The monoclonal antibody group had a lower incidence rate of adverse reactions than the placebo group [odds ratio (OR): 0.81; 95% confidence interval (CI): 0.63–1.03; p = 0.09)]. Clinical response was higher in the ETR group than in the placebo group (OR: 1.56; 95% CI: 1.20–2.02; p = 0.0009), and endoscopic improvement was more favorable in the ETR group (OR: 1.88; 95% CI: 1.45–2,45; p < 0.00001). A higher rate of endoscopic remission was found in the ETR group than in the placebo group (OR: 2.48; 95% CI: 1.75–3.50; p < 0.00001); histological remission was significantly higher in the ETR group than in the placebo group (OR: 2.11; 95% CI: 1.55–2.86; p < 0.00001). The placebo group had a lower rate of positive antidrug antibodies (OR: 1.31; 95% CI: 0.79–2.17; p < 0.29), and the incidence of complications was significantly higher in the ETR group compared with the placebo group (OR: 2.05; 95% CI: 1.48–2.83; p < 0.0001). Conclusion: Given the heterogeneity and potential biases in the included studies, gastroenterologists should cautiously tailor drug delivery strategies based on their clinical experience and the unique needs of individual patients. PROSPERO registration: CRD42023396100

show abstract

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

Cited by 6 publications

References 93 publications

Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease

Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease

Dopamine β-hydroxylase shapes intestinal inflammation through modulating T cell activation

Meta-analysis of etrolizumab versus placebo in ulcerative colitis: safety and efficacy outcomes

Contact Info

Product

Resources

About